Unlocking the Power of the Immune System

Nectin Therapeutics develops a series of novel immunotherapeutic biological drugs, targeting receptors from the nectin protein family with the intention to set a new standard for efficacy and patient response rates across various solid and hematological cancers.

The Company is developing a diverse pipeline of targeted antibodies based on the nectin pathways. These antibodies overcome inhibitory pathways deployed by the tumors and allow immune cells to effectively destroy cancer cells.